FDA REVITALIZATION ACT COULD PASS VIA FISCAL 1989 APPROPRIATIONS BILL
Executive Summary
FDA REVITALIZATION ACT COULD PASS VIA FISCAL 1989 APPROPRIATIONS BILL, under an agreement between Sen. Hatch (R-Utah) and Labor & Human Resources Committee Chairman Kennedy (D-Mass.). In June 6 letter to Senate Agriculture appropriations Subcommittee Chairman Burdick (D-N.D.), Kennedy and Hatch asked the seven provisions in S 2468 be included in the FDA appropriation for 1989. Kennedy reportedly has indicated that the Hatch bill's federal preemption/uniformity and de minimis provisions should not circumvent the legislative process and that he will consider scheduling Labor & Human Resources Committee action on those subjects separately. Kennedy, however, agrees with Hatch on seeking the appropriations process for seven provisions: (1) Planning a "consolidated" FDA Washington facility; (2) establishing a senior biomedical scientist service; (3) increasing agency staff; (4) funds to help FDA facilitate approvals for small businesses; (5) funding for demonstration projects for developing public or private cooperatives; (6) funding for scientist training grants; and (7) authorizing FDA appointment of scientific peer review groups. Kennedy's quick support for the FDA revitalization proposal brings the Massachusetts Democrat back into the FDA area. In the late 1970's, Kennedy proposed a bill which would have broken the agency into several separate agencies.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth